Rejuvenate Bio secures new funding and Merck partnership in anti-aging gene therapy push. Rejuvenate Bio lands fresh investment and a Merck partnership, signaling growing pharma confidence in gene therapy approaches to aging. 2026-06-24 Rejuvenate Bio, a longevity-focused biotech developing gene therapy interventions targeting the biology of aging, has secured new funding alongside a strategic partnership with pharmaceutical giant Merck, according to reporting from Longevity.Technology. The announcement marks one of the more significant validation moments for the aging gene therapy field in recent months, with a major established pharma player now formally aligned with a company working at the frontier of biological age reversal. For industry observers, the Merck partnership carries particular weight. Large pharmaceutical companies have historically maintained a cautious distance from longevity biotechs, preferring to watch the science mature before committing resources. A named partnership with Merck suggests that calculus is shifting. Whether the collaboration involves co-development, licensing arrangements, or research access remains to be detailed publicly, but the signal it sends to the broader agetech and longevity investment community is difficult to overstate. Rejuvenate Bio has built its platform around gene therapy approaches that aim to address aging at a systemic level rather than targeting individual age-related diseases in isolation. The company's scientific foundation draws on work exploring how specific gene interventions can influence biological processes associated with aging across multiple organ systems simultaneously. This systems-level framing has distinguished Rejuvenate Bio from many peers in the longevity biotech space who focus on single-pathway or single-disease approaches. The timing of this announcement fits within a broader pattern of accelerating institutional interest in longevity biotechnology through 2025 and into 2026. Funding rounds across the sector have grown in both frequency and scale, and the entry of established pharmaceutical partners into formal collaborations represents the next logical phase of market maturation. For agetech professionals working in adjacent areas - from senior living technology to AI-enabled care platforms - the continued validation of the longevity biotech space reinforces the overall investment narrative around aging as a defining market category. The practical implications for near-term clinical translation are still developing. Gene therapy approaches to aging face meaningful regulatory and safety questions that will take years of clinical work to resolve. However, partnerships like the one announced between Rejuvenate Bio and Merck typically accelerate that process by bringing additional scientific infrastructure, regulatory experience, and capital to bear on exactly those challenges. As the agetech industry continues to expand across both care technology and longevity science, deals of this nature serve as important connective tissue between the cutting edge of research and the commercial pathways that will eventually deliver interventions to aging populations at scale. Get the AgeTech Digest Funding rounds, product launches, and industry moves - every week, free.

Lifespan portfolio company Rejuvenate Bio closes $6 million financing and R&D collaboration with Merck Animal Health. Jun 11, 2026, 09:59 ET Milestone financing and R&D collaboration advances gene therapy programs targeting chronic and age-related diseases in companion animals. NORWALK, Conn., June 11, 2026 /CNW/ - Lifespan Vision Ventures (LVV), an investment firm focused on therapeutics that improve human healthspan, congratulates its portfolio company Rejuvenate Bio on the successful close of a $6 million financing round and the announcement of a strategic research and development collaboration with Merck Animal Health. The financing round was led by VCapital, with participation from Merck Animal Health, Connecticut Innovations, and Digitalis. Proceeds will support continued advancement of Rejuvenate Bio's gene therapy platform and pipeline, including treatments designed to address chronic and age-associated diseases in companion animals. Alongside the financing, Rejuvenate Bio and Merck Animal Health have entered into a strategic R&D collaboration focused on advancing a novel gene therapy program in animal health, leveraging Rejuvenate Bio's proprietary platform technologies and translational expertise. Andrew Worden, Founding Partner at Lifespan Vision Ventures stated, "We are proud to see Rejuvenate Bio reach this important milestone. The confidence shown by Merck Animal Health - both as an investor and a collaborator - speaks to the strength of the team and the promise of their science. Lifespan Vision Ventures is delighted to continue supporting their mission to address some of the most significant unmet needs in companion animal and human health." Rejuvenate Bio is developing gene therapies aimed at extending healthy lifespan and treating chronic diseases across both veterinary and human health applications. The company's approach focuses on modifying biological pathways associated with aging through targeted genetic interventions. About Lifespan Vision Ventures Lifespan Vision Ventures is a global venture capital firm investing in early-stage biotechnology companies developing breakthrough technologies to prevent and treat age-related diseases. The firm partners with visionary founders advancing science-driven solutions that promote healthy aging and extend human healthspan. About Rejuvenate Bio Rejuvenate Bio is a biotechnology company dedicated to developing novel gene therapies for chronic age-related diseases. Rejuvenate Bio has built a gene therapy pipeline with huge potential in chronic disease by utilizing clinically validated gene targets and a delivery approach that ensures well tolerated, durable expression. Founded on scientific research developed at the Wyss Institute at Harvard Medical School, Rejuvenate Bio has developed groundbreaking therapies to treat chronic age-related disease in both humans and animals. The company is headquartered in San Diego, CA. SOURCE LifeSpan Vision Ventures